Non-Viral Gene Delivery Technologies Market Report 2026

Non-Viral Gene Delivery Technologies Market Overview

• Non-Viral Gene Delivery Technologies market size has reached to $4.57 billion in 2025 • Expected to grow to $9.26 billion in 2030 at a compound annual growth rate (CAGR) of 15.1% • Growth Driver: Increasing Demand For Personalized Medicine Fueling The Growth Of The Market Due To Rising Need For Safer, Targeted Gene Therapies • Market Trend: Advancements In Non-Viral Genetic Medicine Platforms Enhancing Gene Therapy Safety And Precision • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Non-Viral Gene Delivery Technologies Market?

Non-viral gene delivery technologies are methods of transferring genetic material into cells without using viruses as carriers. They minimize safety risks and immune reactions linked to viruses while enabling precise and controlled delivery. Their main goal is to alter or regulate gene expression for treating genetic diseases and advancing cell-based therapies. The main product types of non-viral gene delivery technologies are reagents and kits, delivery devices, and pre-formulated nanoparticles. Reagents and kits are chemical formulations that are ready to use and are intended to introduce genetic material into cells without the use of viruses. It is delivered through various delivery modes, including in vitro, in vivo, and ex vivo, with various technologies such as electroporation, lipid-based transfection, polymer-based transfection, physical methods (microinjection and gene gun), and nanoparticles. It is applicable in various applications, including gene therapy, deoxyribonucleic acid (DNA) vaccines, ribonucleic acid interference (RNAi), clustered regularly interspaced short palindromic repeats (CRISPR) or Cas9 gene editing, and protein expression, and is used by several end users, including biotechnology and biopharmaceutical companies, research and academic institutes, and others.

What Is The Non-Viral Gene Delivery Technologies Market Growth Forecast?

The non-viral gene delivery technologies market size is expected to see rapid growth in the next few years. It will grow to $9.26 billion in 2030 at a compound annual growth rate (CAGR) of 15.1%. The growth in the forecast period can be attributed to development of advanced lipid and polymer nanoparticles, expansion of pre-formulated nanoparticle technologies, rising investment in gene editing and rnai therapeutics, increasing demand for personalized gene therapy solutions, integration of high-throughput and automated delivery platforms. Major trends in the forecast period include increasing adoption of lipid-based and polymer-based non-viral delivery systems, growth in crispr and cas9 gene editing applications, rising demand for rnai and dna vaccine delivery platforms, expansion of ex-vivo and in-vivo gene therapy research, development of cell-specific and targeted gene delivery reagents.

Global Non-Viral Gene Delivery Technologies Market Segmentation

1) By Product: Reagents And Kits, Delivery Devices, Pre-Formulated Nanoparticles 2) By Delivery: In-Vitro, In-Vivo, Ex-Vivo 3) By Technology: Electroporation, Lipid-Based Transfection, Polymer-Based Transfection, Physical Methods (Microinjection, Gene Gun), Nanoparticles 4) By Application: Gene Therapy, Deoxyribonucleic Acid (DNA) Vaccines, Ribonucleic Acid Interference (RNAi), Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) Or Cas9 Gene Editing, Protein Expression 5) By End-Use: Biotechnology And Biopharmaceutical Companies, Research And Academic Institutes, Other End-Uses Subsegments: 1) By Reagents And Kits: Transfection Reagents, Plasmid Deoxyribonucleic Acid (DNA) Kits, Messenger Ribonucleic Acid (RNA) Delivery Kits, Small Interfering Ribonucleic Acid (RNA) Delivery Kits, Clustered Regularly Interspaced Short Palindromic Repeats Associated Protein Reagents, Cell-Specific Delivery Reagents 2) By Delivery Devices: Electroporation Systems, Microinjection Systems, Gene Guns Or Biolistic Delivery Devices, Ultrasound-Mediated Delivery Devices, Hydrodynamic Gene Delivery Systems 3) By Pre-Formulated Nanoparticles: Lipid-Based Nanoparticles, Polymer-Based Nanoparticles, Gold-Based Nanoparticles, Dendrimer-Based Nanoparticles, Carbon Nanotube-Based Nanoparticles, Inorganic Compound-Based Nanoparticles

What Is The Driver Of The Non-Viral Gene Delivery Technologies Market?

The increasing demand for personalized medicine is expected to propel the growth of the non-viral gene delivery technologies market going forward. Personalized medicine is a medical approach that customizes prevention, diagnosis, and treatment based on a person’s unique genetic makeup, lifestyle, and environmental influences. Increasing demand for personalized medicine is driven by advancements in genomic sequencing technologies, which allow for more accurate diagnosis, targeted therapies, and improved treatment outcomes tailored to individual patients. The growing focus on personalized medicine is driving demand for non-viral gene delivery technologies, as they offer safer and more adaptable methods to deliver therapeutic genes tailored to an individual’s genetic profile, without the risks associated with viral vectors. For instance, in February 2024, according to the Personalized Medicine Coalition, a US-based non-profit organization, the Food and Drug Administration (FDA) approved 16 novel personalized therapies for patients with rare diseases in 2023, compared to 6 in 2022. Therefore, the increasing demand for personalized medicine is driving the growth of the non-viral gene delivery technologies industry.

Key Players In The Global Non-Viral Gene Delivery Technologies Market

Major companies operating in the non-viral gene delivery technologies market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Evonik Industries AG, Moderna Inc., Lonza Group AG, Bio-Rad Laboratories Inc., Takara Bio Inc., GenScript Biotech Corporation, ReCode Therapeutics Inc., Altogen Biosystems Inc., Generation Bio, Indee Labs Inc.

Global Non-Viral Gene Delivery Technologies Market Trends and Insights

Major companies operating in the non-viral gene delivery market are focusing on developing advanced solutions such as non-viral genetic medicine platforms to improve the safety and efficiency of gene therapies. A non-viral genetic medicine platform is a technology that introduces therapeutic genes or nucleic acids into cells without viruses, reducing immune reactions and safety concerns, enabling precise and controlled gene therapy delivery for multiple diseases. For instance, in October 2023, Generation Bio Co., a US-based biotechnology company that develops genetic medicines, launched immune-quiet DNA (iqDNA). This novel DNA is an optimized form of their closed-ended DNA (ceDNA) that evades innate immune detection, showing cytokine levels and tolerability comparable to chemically modified mRNA in mice and non-human primates when delivered via their lipid nanoparticle (LNP) system. Due to iqDNA's superior tolerability, Generation Bio is advancing this as the primary DNA cargo in all its programs, including its lead hemophilia A program.

What Are Latest Mergers And Acquisitions In The Non-Viral Gene Delivery Technologies Market?

In September 2023, SOHM Inc., a US-based pharmaceutical company specializing in the manufacturing and distribution of generic and private-label drugs, acquired ABBIE Inc. for an undisclosed amount. With this acquisition, SOHM strengthens its capabilities in non-viral gene delivery technologies, positioning the company to advance innovative gene-editing solutions and expand its presence in the growing genetic therapeutics market. ABBIE Inc. is a US-based gene-editing platform that can deliver genetic payloads using non-viral vectors.

Regional Insights

North America was the largest region in the non-viral gene delivery technologies market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Non-Viral Gene Delivery Technologies Market?

The non-viral gene delivery technologies market consists of revenues earned by entities by providing services such as genetic material formulation, delivery system development, and transfection optimization. The market value includes the value of related goods sold by the service provider or included within the service offering. The non-viral gene delivery technologies market also includes sales of lipid nanoparticles, polymer-based carriers, electroporation devices, and microinjection systems. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Non-Viral Gene Delivery Technologies Market Report 2026?

The non-viral gene delivery technologies market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the non-viral gene delivery technologies industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.